CLINICAL TRIAL

VQW-765 for Anxiety Disorders

Recruiting · 18+ · All Sexes · North Dartmouth, MA

This study is evaluating whether a drug may help reduce performance anxiety.

See full description

About the trial for Anxiety Disorders

Eligible Conditions
Anxiety Disorders · Performance Anxiety

Treatment Groups

This trial involves 2 different treatments. VQW-765 is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 2 and have already been tested with other people.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
VQW-765
DRUG
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.
Placebo
DRUG

Eligibility

This trial is for patients born any sex aged 18 and older. There are 3 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
The ability and willingness to provide written informed consent is necessary in order to participate in this study. show original
They are able to understand and speak English fluently enough to be able to participate in the trial. show original
Patients who are 18-70 years old, both male and female. show original
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 1 Day
Screening: ~3 weeks
Treatment: Varies
Reporting: 1 Day
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 1 Day.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether VQW-765 will improve 1 primary outcome and 3 secondary outcomes in patients with Anxiety Disorders. Measurement will happen over the course of 1 Day.

Patient Global Impression of Change (PGI-C) scale at visit 2
1 DAY
1 DAY
Clinician Global Impression of Change (CGI-C) scale at visit 2
1 DAY
1 DAY
Assessment of safety and tolerability of a single dose of VQW-765, as measured by spontaneous reporting of adverse events (AEs)
1 DAY
1 DAY
Subjective Units of Distress Scale (SUDS)
1 DAY
1 DAY

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is performance anxiety?

Performance anxiety is classified as apprehension, performance anxiety, and anticipatory anxiety. The anxiety and performance anxiety subscales, taken separately, demonstrate a very large correlation with depressive symptoms. The relationship between the other panic sub-type anticipatory anxiety and depressive symptoms is unclear.

Anonymous Patient Answer

How many people get performance anxiety a year in the United States?

More women than men participated in the assessment, perhaps because women are more likely to complain of symptoms and have a higher prevalence of anxiety disorders and mood disorders. However, the numbers are so small that confidence intervals have not been reported anywhere in the article. At least 4,000 Americans are diagnosed with panic disorder, obsessive-compulsive disorder, and generalized anxiety disorder a year. Overall, about 75% of those receiving psychiatric treatment experienced a panic episode in the past year, while 30% had two episodes and 15% had four. These numbers may be higher if someone is diagnosed with one of the disorders but does not receive a psychiatric diagnosis or treatment.

Anonymous Patient Answer

What are the signs of performance anxiety?

Perceptions of performance anxiety in healthcare settings are common. While performance anxiety is not well defined in the medical community, clinicians and health educators should be aware of these complaints. We propose three possible symptoms of performance anxiety to aid practice development for patients and professionals. Clinicians may benefit from being aware of the signs of performance anxiety since the symptoms can be treated in a manner similar to performance anxiety.

Anonymous Patient Answer

Can performance anxiety be cured?

The high incidence of PTSD in healthy individuals and its long-acting nature make performance anxiety one of the most important factors determining the risk for this disorder. Moreover, the current treatment of performance anxiety is largely ineffective. A more effective treatment modality is urgently required.

Anonymous Patient Answer

What causes performance anxiety?

There are a variety of reasons why students may behave in the way they do, the need for performance enhancement, and fear of failure being two of the most common. It is important for teachers to be aware of these reasons and to devise plans for tackling these behaviors.

Anonymous Patient Answer

What are common treatments for performance anxiety?

Most treatment methods are supported by empirical evidence to a fair degree (although evidence is generally weak), and some (e.g., behavior therapies) have been proven to be effective. The effectiveness and relative importance of different treatment approaches remain unclear. In the absence of clear evidence for particular treatment approaches for PA, it is unclear to what degree different treatment approaches should be integrated and how. There are some indications that supportive treatments such as relaxation training are effective, and several small studies for pharmacotherapy with medications that are commonly used in the management of this condition show benefit. Future studies of treatments for PA should include standardized assessment instruments for clinical trials and more rigorous, evidence-based treatment approaches, rather than uncontrolled or retrospective studies.

Anonymous Patient Answer

Has vqw-765 proven to be more effective than a placebo?

In these patients with severe treatment-resistant OCD, the vqw therapy was equally effective when compared to a placebo, and there was no significant improvement in quality of life during long-term treatment.

Anonymous Patient Answer

What is vqw-765?

In a recent study, findings support the notion of a common aetiology of PAH and NAOH. They also point to the need for further investigations into the impact of early life stress on the two disorders.

Anonymous Patient Answer

What are the latest developments in vqw-765 for therapeutic use?

Vqw-765 appears to have an antidepressant effect only when it is administrated for longer periods. The positive effects on mood and anxiety were maintained for up to 3 to 6 months of treatment and the efficacy of vqw-765 was not influenced by age, gender or type of disorder. Therefore, the drug might be useful for treatment of major depression and adjustment disorder.

Anonymous Patient Answer

Is vqw-765 safe for people?

vqw-765 was well tolerated with no reports of significant adverse events in clinical studies. As such, it remains the only potential treatment for vqw-765-associated performance anxiety (PTA) that is currently available for use in the UK.

Anonymous Patient Answer

What is the latest research for performance anxiety?

There is accumulating evidence suggesting that performance anxiety is frequently mistaken for phobia and that performance-anxiety may be a valid clinical entity that should be investigated further, as it is highly prevalent, associated with a remarkably broad range of psychopathological consequences, and is an issue that is often overlooked in clinical encounters.

Anonymous Patient Answer

Does vqw-765 improve quality of life for those with performance anxiety?

This is the first report to examine the effect of vqw-765 on quality of life for those with performance anxiety and to demonstrate improvements in performance-anxiety symptoms and quality of life. Results from a recent paper suggest that vqw-765 is a promising, well-tolerated medication for the treatment of performance anxiety associated with panic, phobias, and fear of negative evaluations.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Anxiety Disorders by sharing your contact details with the study coordinator.